| Title |
A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer
|
|---|---|
| Published in |
Breast Cancer Research and Treatment, July 2012
|
| DOI | 10.1007/s10549-012-2126-1 |
| Pubmed ID | |
| Authors |
Martin Schuler, Ahmad Awada, Philipp Harter, Jean Luc Canon, Kurt Possinger, Marcus Schmidt, Jacques De Grève, Patrick Neven, Luc Dirix, Walter Jonat, Matthias W. Beckmann, Jochen Schütte, Peter A. Fasching, Nina Gottschalk, Tatiana Besse-Hammer, Frank Fleischer, Sven Wind, Martina Uttenreuther-Fischer, Martine Piccart, Nadia Harbeck |
| Abstract |
Afatinib (BIBW 2992) is an ErbB-family blocker that irreversibly inhibits signaling from all relevant ErbB-family dimers. Afatinib has demonstrated preclinical activity in human epidermal growth factor receptor HER2 (ErbB2)-positive and triple-negative xenograft models of breast cancer, and clinical activity in phase I studies. This was a multicenter phase II study enrolling patients with HER2-negative metastatic breast cancer progressing following no more than three lines of chemotherapy. No prior epidermal growth factor receptor-targeted therapy was allowed. Patients received 50-mg afatinib once daily until disease progression. Tumor assessment was performed at every other 28-day treatment course. The primary endpoint was clinical benefit (CB) for ≥4 treatment courses in triple-negative (Cohort A) metastatic breast cancer (TNBC) and objective responses measured by Response Evaluation Criteria in Solid Tumors in patients with HER2-negative, estrogen receptor-positive, and/or progesterone receptor-positive breast cancer (Cohort B). Fifty patients received treatment, including 29 patients in Cohort A and 21 patients in Cohort B. No objective responses were observed in either cohort. Median progression-free survival was 7.4 and 7.7 weeks in Cohorts A and B, respectively. Three patients with TNBC had stable disease for ≥4 treatment courses, one of them for 12 courses (median 26.3 weeks; range 18.9-47.9 weeks). The most frequently observed afatinib-associated adverse events (AEs) were gastrointestinal and skin-related side effects, which were manageable by symptomatic treatment and dose reductions. Afatinib pharmacokinetics were comparable to those observed in previously reported phase I trials. In conclusion, afatinib had limited activity in HER2-negative breast cancer. AEs were generally manageable and mainly affected the skin and the gastrointestinal tract. |
Mendeley readers
The data shown below were compiled from readership statistics for 66 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 2% |
| Unknown | 65 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 17 | 26% |
| Student > Ph. D. Student | 16 | 24% |
| Student > Master | 7 | 11% |
| Other | 5 | 8% |
| Student > Postgraduate | 4 | 6% |
| Other | 10 | 15% |
| Unknown | 7 | 11% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 25 | 38% |
| Agricultural and Biological Sciences | 11 | 17% |
| Biochemistry, Genetics and Molecular Biology | 8 | 12% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 6% |
| Nursing and Health Professions | 2 | 3% |
| Other | 7 | 11% |
| Unknown | 9 | 14% |
Attention Score in Context
This research output has an Altmetric Attention Score of 12. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 May 2022.
All research outputs
#2,459,786
of 22,789,076 outputs
Outputs from Breast Cancer Research and Treatment
#366
of 4,655 outputs
Outputs of similar age
#16,490
of 164,321 outputs
Outputs of similar age from Breast Cancer Research and Treatment
#9
of 53 outputs
Altmetric has tracked 22,789,076 research outputs across all sources so far. Compared to these this one has done well and is in the 88th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,655 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.2. This one has done particularly well, scoring higher than 91% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 164,321 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 89% of its contemporaries.
We're also able to compare this research output to 53 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 83% of its contemporaries.